Literature DB >> 9736873

Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset.

R Brookmeyer1, S Gray, C Kawas.   

Abstract

OBJECTIVES: The goal of this study was to project the future prevalence and incidence of Alzheimer's disease in the United States and the potential impact of interventions to delay disease onset.
METHODS: The numbers of individuals in the United States with Alzheimer's disease and the numbers of newly diagnosed cases that can be expected over the next 50 years were estimated from a model that used age-specific incidence rates summarized from several epidemiological studies, US mortality rates, and US Bureau of the Census projections.
RESULTS: in 1997, the prevalence of Alzheimer's disease in the United States was 2.32 million (range: 1.09 to 4.58 million); of these individuals, 68% were female. It is projected that the prevalence will nearly quadruple in the next 50 years, by which time approximately 1 in 45 Americans will be afflicted with the disease. Currently, the annual number of new incident cases in 360,000. If interventions could delay onset of the disease by 2 years, after 50 years there would be nearly 2 million fewer cases than projected; if onset could be delayed by 1 year, there would be nearly 800,000 fewer prevalent cases.
CONCLUSIONS: As the US population ages, Alzheimer's disease will become an enormous public health problem. interventions that could delay disease onset even modestly would have a major public health impact.

Entities:  

Mesh:

Year:  1998        PMID: 9736873      PMCID: PMC1509089          DOI: 10.2105/ajph.88.9.1337

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  43 in total

Review 1.  Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society.

Authors:  G W Small; P V Rabins; P P Barry; N S Buckholtz; S T DeKosky; S H Ferris; S I Finkel; L P Gwyther; Z S Khachaturian; B D Lebowitz; T D McRae; J C Morris; F Oakley; L S Schneider; J E Streim; T Sunderland; L A Teri; L E Tune
Journal:  JAMA       Date:  1997 Oct 22-29       Impact factor: 56.272

2.  The US economic and social costs of Alzheimer's disease revisited.

Authors:  R L Ernst; J W Hay
Journal:  Am J Public Health       Date:  1994-08       Impact factor: 9.308

3.  Estrogen deficiency and risk of Alzheimer's disease in women.

Authors:  A Paganini-Hill; V W Henderson
Journal:  Am J Epidemiol       Date:  1994-08-01       Impact factor: 4.897

4.  Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: a population-based case-control study.

Authors:  D E Brenner; W A Kukull; A Stergachis; G van Belle; J D Bowen; W C McCormick; L Teri; E B Larson
Journal:  Am J Epidemiol       Date:  1994-08-01       Impact factor: 4.897

5.  Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study.

Authors:  K Andersen; L J Launer; A Ott; A W Hoes; M M Breteler; A Hofman
Journal:  Neurology       Date:  1995-08       Impact factor: 9.910

6.  Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects.

Authors:  V W Henderson; A Paganini-Hill; C K Emanuel; M E Dunn; J G Buckwalter
Journal:  Arch Neurol       Date:  1994-09

7.  Age-specific incidence of Alzheimer's disease in a community population.

Authors:  L E Hebert; P A Scherr; L A Beckett; M S Albert; D M Pilgrim; M J Chown; H H Funkenstein; D A Evans
Journal:  JAMA       Date:  1995-05-03       Impact factor: 56.272

8.  Incidence of dementia and Alzheimer's disease in elderly community residents of south-western France.

Authors:  L Letenneur; D Commenges; J F Dartigues; P Barberger-Gateau
Journal:  Int J Epidemiol       Date:  1994-12       Impact factor: 7.196

9.  The economic burden of Alzheimer's disease care.

Authors:  D P Rice; P J Fox; W Max; P A Webber; D A Lindeman; W W Hauck; E Segura
Journal:  Health Aff (Millwood)       Date:  1993       Impact factor: 6.301

10.  Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama Study.

Authors:  T Yoshitake; Y Kiyohara; I Kato; T Ohmura; H Iwamoto; K Nakayama; S Ohmori; K Nomiyama; H Kawano; K Ueda
Journal:  Neurology       Date:  1995-06       Impact factor: 9.910

View more
  473 in total

1.  Okadaic acid induces tau phosphorylation in SH-SY5Y cells in an estrogen-preventable manner.

Authors:  Zhang Zhang; James W Simpkins
Journal:  Brain Res       Date:  2010-05-07       Impact factor: 3.252

Review 2.  The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment.

Authors:  G Stennis Watson; Suzanne Craft
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 3.  Diet and Alzheimer's disease.

Authors:  José A Luchsinger; James M Noble; Nikolaos Scarmeas
Journal:  Curr Neurol Neurosci Rep       Date:  2007-09       Impact factor: 5.081

Review 4.  Clinically asymptomatic vascular brain injury: a potent cause of cognitive impairment among older individuals.

Authors:  Charles DeCarli
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 5.  Perturbations of neural circuitry in aging, mild cognitive impairment, and Alzheimer's disease.

Authors:  Stephanie L Leal; Michael A Yassa
Journal:  Ageing Res Rev       Date:  2013-02-04       Impact factor: 10.895

6.  Self-administered screening for mild cognitive impairment: initial validation of a computerized test battery.

Authors:  Jane B Tornatore; Emory Hill; Jo Anne Laboff; Mary E McGann
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2005       Impact factor: 2.198

Review 7.  Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.

Authors:  Lisa Mosconi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-04       Impact factor: 9.236

8.  Neighborhoods, sleep quality, and cognitive decline: Does where you live and how well you sleep matter?

Authors:  Jaimie C Hunter; Elizabeth P Handing; Ramon Casanova; Maragatha Kuchibhatla; Michael W Lutz; Santiago Saldana; Brenda L Plassman; Kathleen M Hayden
Journal:  Alzheimers Dement       Date:  2018-02-01       Impact factor: 21.566

Review 9.  Dyslipidemia and the risk of Alzheimer's disease.

Authors:  Christiane Reitz
Journal:  Curr Atheroscler Rep       Date:  2013-03       Impact factor: 5.113

Review 10.  Sexual dimorphism in predisposition to Alzheimer's disease.

Authors:  Daniel W Fisher; David A Bennett; Hongxin Dong
Journal:  Neurobiol Aging       Date:  2018-04-17       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.